Autism: The role of cholesterol in treatment

References

• Allen JA, Halverson-Tamboli RA, Rasenick MM. Lipid raft microdomains and neurotransmitter signalling. Nature Reviews Neuroscience 2007; 8: 128–140
   PubMed Web of Science ®Google Scholar
• Centers for Disease Control (CDC). Morbidity and Mortality Weekly Report Surveillance Summaries 2007, http://www.cdc.gov/MMWR/pdf/ss/ss5601.pdf (Accessed February 9)
   Google Scholar
• Chattopadhyay A, Jafurulla M, Kalipatnapu S, Pucadyil TJ, Harikumar KG. Role of cholesterol in ligand binding and G-protein coupling of serotonin1A receptors solubilized from bovine hippocampus. Biochem Biophys Res Commun 2005; 327: 1036–1041
   PubMedGoogle Scholar
• Correa-Cerro LS, Wassif CA, Kratz L, Miller GF, Munasinghe JP, Grinberg A, et al. Development and characterization of a hypomorphic Smith-Lemli-Opitz syndrome mouse model and efficacy of simvastatin therapy. Hum Mol Genet 2006; 15(6)839–851
   PubMedGoogle Scholar
• Filipek PA, Accardo PJ, Ashwal S, Baranek GT, Cook EH, Dawson Jr G, et al. 2000, Practice parameter: Screening and diagnosis of autism: Report of the Quality Standards Subcommittee of the American Academy of Neurology and the Child Neurology Society. Neurology, 55, 468–479
   Google Scholar
• Fitzky BU, Witsch-Baumgartner M, Erdel M, Lee JN, Paik YK, Glossmann H, et al. Mutations in the Delta7-sterol reductase gene in patients with the Smith-Lemli-Opitz syndrome. Proc Natl Acad Sci USA, 95 1998; 14: 8181–8186
   Google Scholar
• Geschwind DH, Sowinski J, Lord C, Iversen P, Shestack J, Jones P, et al. The autism genetic resource exchange: A resource for the study of autism and related neuropsychiatric conditions. American Journal of Human Genetics 2001; 69(2)463–466
   PubMedGoogle Scholar
• Gimpl G, Wiegand V, Burger K, Fahrenholz F. Cholesterol and steroid hormones: Modulators of oxytocin receptor function. Prog Brain Res 2002; 139: 43–55
   PubMedGoogle Scholar
• Hollander E, Bartz J, Chaplin W, Phillips A, Sumner J, Soorya L, et al. Oxytocin increases retention of social cognition in autism. Biol Psychiatry 2007; 61(4)498–503
   PubMed Web of Science ®Google Scholar
• Irons M, Elias ER, Abuelo D, Bull MJ, Greene CL, Johnson VP, et al. Treatment of Smith-Lemli-Opitz syndrome: Results of a multicenter trial. American Journal of Medical Genetics 1997; 68: 311–314
   PubMedGoogle Scholar
• Irons M, Elias ER, Abuelo D, Tint GS, Salen G. Clinical features of the Smith-Lemli-Opitz syndrome and treatment of the cholesterol metabolic defect. International Pediatrics 1995; 10: 28–32
   Google Scholar
• Jira PE, Wevers RA, de Jong J, Rubio-Gozalbo E, Janssen-Zijlstra FS, van Heyst AE, et al. Simvastatin. A new therapeutic approach for Smith-Lemli-Opitz syndrome. Journal of Lipid Research 2000; 41(8)1339–1346
   PubMedGoogle Scholar
• Lord C, Rutter M, Le Couteur A. Autism Diagnostic Interview - Revised: A revised version of a diagnostic interview for caregivers of individuals with possible pervasive developmental disorders. Journal of Autism and Developmental Disorders 1994; 24: 659–685
   PubMed Web of Science ®Google Scholar
• Lund E, Sisfontes L, Reihner E, Bjorkhem I. Determination of serum levels of unesterified lathosterol by isotope dilution-mass spectrometry. Scandinavian Journal of Clinical and Laboratory Investment 1989; 49(2)165–171
   PubMed Web of Science ®Google Scholar
• Marcos J, Guo LW, Wilson WK, Porter FD, Shackleton C. The implications of 7-dehydrosterol-7-reductase deficiency (Smith-Lemli-Opitz syndrome) to neurosteroid production. Steroids 2004; 69: 51–60
   PubMed Web of Science ®Google Scholar
• Muhle R, Trentacoste SV, Rapin I. The genetics of autism. Pediatrics 2004; 113: e472–e486
   PubMed Web of Science ®Google Scholar
• Nowaczyk MJM, Tierney E. Smith-Lemli-Opitz syndrome: Demystifying genetic syndromes. National Association for the Dually Diagnosed Publishing, Kingston, NY 2004; 207–223
   Google Scholar
• Nowaczyk MJM, Waye JS. The Smith-Lemli-Opitz syndrome: A novel metabolic way of understanding developmental biology, embryogenesis and dysmorphology. Clinical Genetics 2001; 59: 75–76
   Google Scholar
• Nwokoro NA, Mulvihill JJ. Cholesterol and bile acid replacement therapy in children and adults with Smith-Lemli-Opitz (SLO/RSH) syndrome. American Journal of Medical Genetics 1997; 68: 315–321
   PubMedGoogle Scholar
• Opitz JM. RSH (so called Smith-Lemli-Opitz) syndrome. Current Opinions in Pediatrics 1999; 11: 353–362
   PubMedGoogle Scholar
• Pisu MG, Serra M. Neurosteroids and neuroactive drugs in mental disorders. Life Science 2004; 74: 3181–3197
   PubMed Web of Science ®Google Scholar
• Ryan AK, Bartlett K, Clayton P, Eaton S, Mills L, Donnai D, et al. Smith-Lemli-Opitz syndrome: A variable clinical and biochemical phenotype. Journal of Medical Genetics 1998; 35: 558–565
   PubMedGoogle Scholar
• Saher G, Brugger B, Lapper-Siefke C, Mobius W, Tozawa R, Wehr MC, et al. High cholesterol level is essential for myelin membrane growth. Nat Neuroscience 2005; 8: 468–475
   PubMed Web of Science ®Google Scholar
• Sikora DM, Pettit-Kekel K, Penfield J, Merkens LS, Steiner RD. The near universal presence of autism spectrum disorders in children with Smith-Lemli-Opitz syndrome. Am J Med Genet Part A 2006; 140: 1511–1518
   PubMedGoogle Scholar
• Sikora DM, Ruggiero M, Petit-Kekel K, Merkens LS, Connor WE, Steiner RD. Cholesterol supplementation does not improve developmental progress in Smith-Lemli-Opitz syndrome. Journal of Pediatrics 2004; 144(6)783–791
   PubMedGoogle Scholar
• Smith DW, Lemli L, Opitz JM. A newly recognized syndrome of multiple congenital anomalies. Journal of Pediatrics 1964; 64: 210–217
   PubMed Web of Science ®Google Scholar
• Strous RD, Golubchik P, Maayan R, Mozes T, Tuati-Werner D, Weizman A, et al. Lowered DHEA-S plasma levels in adult individuals with autistic disorder. European Neuropsychopharmacology 2005; 15: 305–309
   PubMedGoogle Scholar
• Tabin CJ, McMahon AP. Recent advances in hedgehog signalling. Trends in Cell Biology 1997; 7(11)442–446
   PubMedGoogle Scholar
• Tierney E, Bukelis I, Thompson RE, Ahmed K, Aneja A, Kratz L, et al. Abnormalities of cholesterol metabolism in autism spectrum disorders. American Journal of Medical Genetics Part B 2006; 141B: 666–668
   PubMedGoogle Scholar
• Tierney E, Nwokoro NA, Kelley RI. Behavioral phenotype of RSH/Smith-Lemli-Opitz syndrome. Mental Retardation and Developmental Disabilities Research Reviews 2000; 6(2)131–134
   PubMedGoogle Scholar
• Tierney E, Nwokoro NA, Porter FD, Freund LS, Ghuman JK, Kelley RI. Behavior phenotype in the RSH/Smith-Lemli-Opitz syndrome. American Journal of Medical Genetics 2001; 98: 191–200
   PubMed Web of Science ®Google Scholar
• Tint GS, Irons M, Elias ER, Batta AK, Frieden R, Chen TS, et al. Defective cholesterol biosynthesis associated with the Smith-Lemli-Opitz syndrome. New England Journal of Medicine 1994; 330: 107–113
   PubMed Web of Science ®Google Scholar
• Waage-Baudet H, Lauder JM, Dehart DB, Kluckman K, Hiller S, Tint GS, et al. Abnormal serotonergic development in a mouse model for the Smith-Lemli-Opitz syndrome: Implications for autism. International Journal for Developmental Neuroscience 2003; 21: 451–459
   PubMedGoogle Scholar
• Wassif CA, Krakowiak PA, Wright BS, Gewandter JS, Sterner AL, Javitt N, et al. Residual cholesterol synthesis and simvastatin induction of cholesterol synthesis in Smith-Lemli-Opitz syndrome fibroblasts. Mol Genet Metab 2005; 85(2)96–107
   PubMed Web of Science ®Google Scholar
• Wassif CA, Maslen C, Kachilele-Linjewile S, Lin D, Linck LM, Connor WE, et al. Mutations in the human sterol delta7-reductase gene at 11q12–13 cause Smith-Lemli-Opitz syndrome. American Journal of Human Genetics 1998; 63(1)55–62
   PubMedGoogle Scholar
• Zimmerman AW. Autism spectrum disorders. Treatment of pediatric neurologic disorders, S Singer, EH Kossof, AL Hartman, TO Crawford. Taylor and Francis, Boca Raton 2005; 489–494
   Google Scholar